JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors

NCT02904226 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

242

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: JTX-2011
DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: Pembrolizumab

Sponsor

Jounce Therapeutics, Inc.